To explore potential treatment strategies for MRE11-overexpressing oral cancers in vivo, we tested the efficacy of targeting CXCR4 with neutralizing antibody in mice (Fig. 6I). This evidence concerns the gene CXCR4 and lip and oral cavity carcinoma.